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Abstract
Introduction Remifentanil has a rapid onset and short
duration of action, predictable pharmacokinetic/pharmaco-
dynamic profile, and unlike fentanyl, does not accumulate
with repeated or prolonged administration. This study eval-
uated predictors of remifentanil use in surgical patients with
renal or hepatic impairment, or obesity in the United States
who received remifentanil, fentanyl, or the combination.
Methods Data (2010) from the US Healthcare National
Inpatient Database, State Inpatient Database, State Ambu-
latory Surgery Database, and private hospital and Medicaid
databases were used in this analysis. Patients included had
presence of hepatic or renal disease, and/or obesity and
were [5 and B80 years of age.
Results In 2010, 9,274 patients with renal impairment,
1,896 with hepatic impairment, and 6,278 with obesity
were identified. The percentage of surgical patients diag-
nosed with renal disease, hepatic disease, or obesity who
received remifentanil was 41, 28, and 35 %, respectively;
29, 17, and 22 % received both remifentanil and fentanyl,
and 30, 55, and 43 % received fentanyl alone, respectively.
In patients with renal or hepatic disease the probability of
remifentanil use was greater for persons aged [50 years,
with Medicare as primary payer, or who were diagnosed
with obesity (p \ 0.05 all comparisons). In obese patients,
the probability of remifentanil use was greater for persons
aged[50 years or female (both p \ 0.05). For all 3 disease
states, the probability of remifentanil use was lower for
those receiving epidural anesthesia or with Medicaid as
primary payer (p \ 0.05 all comparisons).
Conclusion Remifentanil in combination with fentanyl is
used less than fentanyl in surgical patients with hepatic
impairment or obesity. This is inconsistent with the fact
that the pharmacokinetic/pharmacodynamic features of
remifentanil suggest it is the preferred intraoperative opioid
in these patients. Predictors of remifentanil use in patients
with renal or hepatic impairment, or obesity include older
age, obesity, and Medicare as primary payer. Remifentanil
in combination with fentanyl was significantly less utilized
than fentanyl in persons with Medicaid as primary payer
even though there was a disproportionate enrollment of
beneficiaries with renal or hepatic disease, or obesity in
state Medicaid programs.
Key Points
The pharmacokinetic/pharmacodynamic features of
remifentanil would suggest that it is the preferred
intraoperative opioid versus fentanyl in patients with
renal impairment, hepatic impairment, or obesity;
however, remifentanil alone or in combination with
fentanyl is, in general, used less frequently than
fentanyl.
Predictors of remifentanil use in patients with renal
impairment, hepatic impairment, or obesity include
older age, obesity, and Medicare as primary payer.
Remifentanil in combination with fentanyl was used
significantly less than fentanyl in surgical patients
with Medicaid as primary payer even though there
was a disproportionate enrollment of beneficiaries
with renal or hepatic disease, or obesity in state
Medicaid programs.
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1 Introduction
Remifentanil is a 4-anilidopiperidine l-opioid analgesic
approved for use as an analgesic agent during induction
and maintenance of general anesthesia [1, 2]. It is a fen-
tanyl derivative and its pharmacodynamic effects are, in
general, similar to fentanyl and the other fentanyl cogeners
[1, 3, 4]. However, the pharmacokinetic profile of remi-
fentanil is unique [1–4]. Its metabolism is independent of
the liver and kidneys, unlike other opioids, and it is rapidly
eliminated via blood and tissue nonspecific esterases [1, 2].
The primary metabolic pathway is de-esterification of
remifentanil to remifentanil acid, a relatively inactive
carboxylic acid metabolite with 300- to 4,600-fold less
potency than the parent compound [1]. Almost 90 % of the
drug recovered in urine is remifentanil acid [1]. Remifen-
tanil is not metabolized by plasma cholinesterase (pseu-
docholinesterase) and is not appreciably metabolized by
the liver or lung [2]. Remifentanil is rapidly absorbed and
distributed throughout the body with a mean volume of
distribution at steady state of 350 mL/kg and a clearance of
approximately 40 mL/min/kg [2].
Remifentanil is considered a true short-acting opioid,
with a rapid onset of action of approximately 1 min [1, 3]
and a short offset of action of approximately 5–10 min [2].
Its offset of action is not affected by duration of drug
infusion, and remifentanil does not accumulate with re-
peated and prolonged administration, unlike other opioids
[5, 6]. The context-sensitive half-time of remifentanil is
approximately 3–4 min irrespective of infusion duration [3,
5, 6].
These features of remifentanil would be of benefit to
certain populations of patients, especially at-risk patients
where drug clearance may be substantially reduced due to
illness, organ dysfunction, or concomitant therapy. The
pharmacokinetics of remifentanil are not affected in any
clinically significant way in several at-risk patient groups.
No differences are seen in the pharmacokinetic profile of
patients with or without renal impairment, or in patients
with end-stage renal disease [7, 8]. The pharmacokinetics
of remifentanil and its major metabolite, remifentanil
acid, are unchanged in patients with severe hepatic
impairment [9, 10]. In obese patients, when dosing is
adjusted to ideal body weight, no differences in pharma-
cokinetics are observed between obese and lean patients
[11].
Remifentanil has been shown to be an effective and safe
analgesic component in the anesthetic management of
patients with renal impairment [12], hepatic impairment
[13], and obesity [14–17]. For these patients, where rapid
titration and precise control of analgesia in response to
hemodynamic fluctuations is essential [18–20], as well as
rapid and predictable emergence from anesthesia
regardless of duration of anesthesia, remifentanil may be
better suited than fentanyl as an adjunct in their general
anesthesia requirements.
Fentanyl is widely distributed in the body, with a vol-
ume of distribution at steady state of 4 L/kg [21]. It is
extensively metabolized by the liver with a high hepatic
clearance (approaching that of hepatic blood flow) and a
high hepatic extraction ratio (0.8–1.0) [21]. Unlike remi-
fentanil, the context-sensitive half-time of fentanyl is
dependent on infusion duration, with accumulation and
prolongation of effect increasing as infusion time increases
[6]. The time required for a 50 % reduction in the effect-
site concentration of fentanyl is over 65 times greater than
that of remifentanil [6].
The following study evaluated predictors of remifentanil
use, fentanyl use, or the combination of the two drugs in
surgical patients with renal impairment, hepatic impair-
ment, and/or obesity in the United States.
2 Methods
2.1 Data Source
This study evaluated administrative claims data (January 1,
2010, to December 31, 2010) from the US Healthcare Cost
and Utilization Project’s National Inpatient Database, State
Inpatient Database, and State Ambulatory Surgery Data-
base (US Department of Health and Human Services,
Agency for Healthcare Research and Quality) [22] and
from MarketScan Hospital Drug Database and Market-
Scan State Medicaid Database.
2.2 Study Population
Patients aged [5 and B80 years with renal impairment,
hepatic impairment, and/or obesity were identified by
international classification of disease (ICD-9-CM) codes:
584.x-585.x (renal impairment), 570.x-573.x (hepatic
impairment), and 278.x (body mass index [30 kg/m2 for
obesity) from 8 categories of surgical procedures identified
by ICD-9-CM and/or current procedure terminology codes:
cardiac, general, gynecology, orthopedic, otolaryngology,
neurology, thoracic, and vascular [23]. Patients were
included in the study if they received remifentanil hydro-
chloride, fentanyl, or a combination of remifentanil HCL
and fentanyl for surgical procedures. Patients were exclu-
ded if they were transferred to another facility.
2.3 Assessments
Baseline characteristics and other factors that may be
predictive of patients receiving remifentanil, fentanyl, or
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the combination of these two drugs were evaluated
including age, sex, disease state (renal impairment, hepatic
impairment, obesity), comorbidities (identified by ICD-9-
CM codes), healthcare plan (Medicaid, Medicare, or pri-
vate), use of epidural drugs, and facility characteristics
(hospital or outpatient; bed size, location [urban; rural];
ownership).
2.4 Statistical Analysis
Hierarchical mixed-effects logistic regression analysis was
used to discern factors predictive of receipt of remifentanil,
fentanyl, or the combination in patients with renal
impairment, hepatic impairment, and/or obesity. The a
priori significance level was p \ 0.05. Odds ratio (OR) and
95 % confidence intervals (CI) were adjusted for patient-
level Charlson/Deyo score (index for predicting mortality
by comorbid conditions) and facility characteristics (pub-
lic/private, teaching/nonteaching, urban/rural). Analysis
was conducted using SAS (version 9.1.3; SAS Research
Institute, Cary, NC, USA), and STATA (version 12;
STATA Corporation, LP, College Station, TX, USA). Data
on percentage of patients receiving remifentanil, fentanyl,
or the combination are presented using descriptive statistics
only.
3 Results
A total of 9,274 patients were identified in 2010 with renal
impairment, 1,896 with hepatic impairment, and 6,278 with
obesity (Table 1). There were slightly more male than
female patients in each of the disease groups, and the mean
age of patients was highest in the renal-impairment patients
and lowest in the obese patients.
Of the patients identified with renal impairment, 41 %
received remifentanil, 29 % received a combination of
remifentanil and fentanyl, and 30 % received fentanyl
alone (Fig. 1). Twenty-eight percent of the patients iden-
tified with hepatic impairment received remifentanil, while
17 % received the combination of the two drugs and 55 %
received fentanyl alone. Among the obese patients, 35, 22,
and 43 % received remifentanil, a combination of remif-
entanil and fentanyl, or fentanyl alone, respectively.
3.1 Predictors of Remifentanil Use in Surgical Patients
with Renal Impairment, Hepatic Impairment,
or Obesity
In patients with renal impairment or hepatic impairment,
the probability of remifentanil or combination remifentanil
and fentanyl use versus fentanyl alone was significantly
greater for patients aged [50 years, diagnosed with
obesity, or having Medicare as their primary payer (relative
to private payer) (Table 2). The probability of remifentanil
or combination remifentanil and fentanyl use versus fen-
tanyl in both groups of patients was significantly lower for
those receiving epidural anesthesia and for those having
Medicaid as the primary payer.
The probability of remifentanil or combination remi-
fentanil and fentanyl use versus fentanyl alone was sig-
nificantly greater for obese patients that were female and
aged[50 years, (Table 2) and significantly lower for obese
patients receiving epidural anesthesia or having Medicaid
as their primary payer.
4 Discussion
The results of this study found that remifentanil, with or
without fentanyl, was used in 70 % of the surgical patients
with renal impairment, 45 % of those with hepatic
impairment, and 57 % of those with obesity. The numbers
for patients with hepatic impairment or obesity were lower
than expected. In severe liver failure patients, single bolus
or low-dose fentanyl can be used; however, accumulation
of fentanyl is a concern with repeated or high doses [24].
The metabolism of remifentanil is unchanged in severe
liver disease patients as metabolism is via tissue and blood
esterases, making it an attractive opioid component of the
anesthetic regimen for patients with hepatic impairment
[24].
Obesity was found to be a positive predictor of rem-
ifentanil use. Obesity is associated with a number of
comorbid conditions that affect the administration of
anesthesia including restrictive lung disease, obstructive
sleep apnea, diabetes, hypertension, pulmonary hyperten-
sion, cardiomegaly, liver disease, and delayed gastric
emptying [25, 26]. Obese patients also have a higher
prevalence of cardiovascular disease, including hyperten-
sion, arrhythmias, stroke, heart failure, and coronary
artery disease [26], which can contribute to difficulties in
maintaining a stable circulatory status in these patients.
Airway procedures may be more difficult in these patients
and they may have more difficulty breathing during
anesthesia [26]. Operating time may be longer in an obese
patient due to technical challenges faced by the surgeon
when the anatomy is distorted or hidden behind excessive
fat. The longer exposure to general anesthesia may cause
delayed awakening of the patient or lead to over-sedation
and subsequent postoperative complications, including
respiratory depression [18]. Use of remifentanil has been
shown to result in shorter extubation times, earlier
mobilization of patients, and potential minimization of
postoperative complications such as respiratory depression
or hypoxemia [15, 18, 19].
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These features are also important for patients with organ
impairment, many of whom are advanced in age. Elderly
patients have reduced organ functional reserves and
reduced compensatory mechanisms in response to stress,
and medications are cleared from the body at a slower rate
[25, 27]. There is an increased risk for postoperative
complications in the elderly that includes adverse drug
reactions, postoperative cognitive dysfunction, and delir-
ium [25, 27]. Use of drugs associated with delirium in the
elderly such as long-acting opioids, benzodiazepines and
anticholinergics should be limited [25]. It is important that
the anesthetic regimen used for elderly patients provides
intraoperative stability combined with rapid emergence to
minimize the incidence of postoperative cognitive impair-
ment and side effects [27]. Recovery time with remifen-
tanil-nitrous oxide anesthesia has been shown to be shorter
than with fentanyl-isoflurane-nitrous oxide anesthesia in a
study of elderly patients aged 65 years and older under-
going spinal surgery [28]. Patients receiving the remifen-
tanil-based regimen had shorter time to eye opening,
extubation, and spontaneous respiration versus the fenta-
nyl-based regimen [28]. Such results support the finding
from this study that older age ([50 years) is a predictor of
remifentanil use.
Remifentanil, alone or in combination with fentanyl,
was used significantly less than fentanyl in patients for
whom the primary payer was Medicaid, even though there
was a disproportionate enrollment of beneficiaries with
renal or hepatic disease and/or obesity in state Medicaid
programs. These payor results would suggest that access to
remifentanil may be an issue for low-income patients.
Perceived differences in cost for remifentanil versus fen-
tanyl may be a barrier to remifentanil use. The drug cost of
remifentanil is higher than that of fentanyl; however, drug
costs are only a small part of total healthcare costs [20].
Synergistic effects of anesthetic drugs and use of con-
comitant drugs all affect total costs. In addition, differences
in time the patient is in surgery and differences in recovery
and postoperative side effects all affect hospital, surgical,
and postoperative expenditures.
Unfortunately, hardly any studies published in the
United States evaluate in a comprehensive manner overall
hospital or all anesthesia-related cost comparisons between
remifentanil and fentanyl. The few existing American
studies that analyze other costs in addition to opioid drug
costs do suggest that when other costs are taken into
account, such as total hospital costs or total anesthesia-
related drug costs, the two drugs are comparable [29–31].
Engoren et al. [30] evaluated the cost of fast-track car-
diac surgery in 90 adult patients who received remifentanil-
based, sufentanil-based, or fentanyl-based anesthesia. The
investigators found that although the median opioid and
anesthetic costs of remifentanil were higher than those of
fentanyl, total hospital cost (sum of direct variable cost for
Table 1 Patient demographics
and baseline characteristics
a Categorized by ICD-9-CM
codes: 570.x-573.x for hepatic
disease, 584.x-585.x for renal
disease, 278.x (body mass index








Mean ±SD 53.5 ± 13.5 49.2 ± 17.8 39.4 ± 15.7
Median 53.0 48.0 37.0
Range 32–74 21–80 16–74
Sex (%)
Male 58 64 53
Payer (%)
Medicaid 76 63 51
Medicare 17 19 22
Private 7 18 27
Epidural anesthesia
Yes (%) 31 28 29
Obesity (278.x)a































Fig. 1 Percentage of renal-impaired, hepatic-impaired, or obese
patients receiving remifentanil, fentanyl, or a combination of
remifentanil and fentanyl
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each item and service used by the patient from preoperative
period through to discharge or death) was comparable
between the two groups. No significant differences were
found in median ventilator times, intensive care unit (ICU)
stays, and hospital stays between the anesthesia regimens.
Reddy et al. [31] evaluated the cost of coronary artery
bypass graft surgery with remifentanil-based anesthesia
versus fentanyl-based anesthesia in 59 adult patients.
Anesthetic costs were higher for remifentanil versus fen-
tanyl; however, pulmonary function testing costs, recovery
room costs, and ward costs were lower with remifentanil
than with fentanyl. Length of stay and other costs such as
medical and surgical supplies, operating room, ICU, lab-
oratory, radiology, pharmacy, and transfusion costs were
similar between the two treatments. Taken together, the
total costs of remifentanil and fentanyl were comparable.
A retrospective cost analysis of a controlled multicenter
clinical study evaluating patients (N = 63) undergoing
craniotomy found that total anesthesia drug-related costs
were less with remifentanil than with fentanyl for all price
considerations except at the lowest average wholesale price
(AWP) of fentanyl [29]. Total drug costs were based on a
range of AWPs for the two opioids as well as all con-
comitant drugs used in the intraoperative and immediate
postoperative periods that were related to the choice of
opioid during surgery.
For certain short duration surgeries, anesthetic costs
alone may be comparable between remifentanil and fen-
tanyl. In a study by Jellish et al. [32], the anesthetic cost of
remifentanil-based total intravenous anesthesia (TIVA)
anesthesia supplemented with low-dose propofol in
patients undergoing otologic procedures (1–2 h proce-
dures) was $69 ± 7 versus $66 ± 5 for propofol-based
TIVA with supplemental fentanyl. Patients receiving the
remifentanil-based anesthesia had better hemodynamic
stability, less movement, and faster emergence from sur-
gery. Postoperative pain scores were mild for both groups,
but higher in the remifentanil group. All other variables
examined were similar, including incidence and severity of
postoperative nausea and vomiting, mean time to hospital
discharge, ambulation without dizziness and other recovery
parameters, and patient satisfaction with anesthesia.
More studies are needed that evaluate aggregate costs of
pharmacotherapy with remifentanil versus fentanyl, not
only in higher-risk patients such as those with renal and
hepatic impairment and obese patients, but also in certain
surgeries where the pharmacokinetic benefits of remifen-
tanil over other opioids may prove advantageous.
A limitation of this study is the retrospective nature of
the analysis. ICD-9-codes were used to identify patients
with renal impairment, including those with acute renal
failure. There is no differentiation between presurgical or
postsurgical occurrence of acute renal failure. It is possible
that some of the patients included in this analysis had this
condition as a consequence of surgery. Due to the fast
offset of effect of remifentanil, another analgesic is
required prior to discontinuation of remifentanil general
anesthesia if postoperative pain is anticipated and remi-
fentanil infusion is not continued into the postoperative
period. Fentanyl may have been used for postoperative pain
Table 2 Patient characteristics
predictive of remifentanil or
combination of remifentanil and




BMI body mass index, CI
confidence interval, OR odds
ratio
* p \ 0.05
a Adjusted for patient-level






b OR and 95 % CI relative to
private payer (e.g., managed
care; health maintenance
organization)





Obesity BMI [ 30
(n = 6,278)
Age, years
0 = \50 1.37 (1.13–1.58)* 1.21 (1.08–1.46)* 1.49 (1.28–1.62)*
1 = C50
Sex
1 = Women 1.05 (0.93–1.12) 0.92 (0.85–1.13) 1.23 (1.07–1.45)*
0 = Men
Payer
Medicaid 0.78 (0.51–0.88)* 0.85 (0.63–0.91)* 0.81 (0.64–0.93)*
Medicare 1.94 (1.56–2.33)* 1.69 (1.37–1.85)* 0.93 (0.78–1.06)
Private (reference)b
Epidural anesthesia
1 = Yes 0.42 (0.27–0.61)* 0.64 (0.52–0.79)* 0.75 (0.61–0.83)*
0 = No
Obesity
1 = Yes 1.19 (1.07–1.35)* 1.36 (1.18–1.63)* N/A
0 = No
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and may be included in the fentanyl plus remifentanil
group; however, no separate evaluation of this parameter
was conducted.
5 Conclusion
The type of analgesic pharmacotherapy should be predi-
cated on the clinical presentation of a given patient (e.g.,
hepatic disease, renal disease, obesity) and the pharmaco-
kinetic and metabolic profile of an agent.
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